Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Abstract
Emerging evidence indicates patients who benefit from antiangiogenic therapies have improved vessel function. To determine how bevacizumab modulates vessel morphology to improve vessel function we conducted a phase II trial of preoperative bevacizumab followed by bevacizumab combined with chemotherapy in HER2-negative breast cancer patients. Our results suggest that the clinical response to bevacizumab may occur through an increase in the extent of vascular normalization primarily in patients with a high baseline tumor microvessel density. If validated, these observations suggest approaches to improve antiangiogenic therapy and to identify patients likely to benefit.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 02, 2015
- Source ID
- 10.1073/pnas.1518808112
Entities
People
- Dan G Duda
- Eren D. Yeh
- Eric Winer
- Giorgio Seano
- Ian E. Krop
- Jane Brock
- Johanna Lahdenrata
- John D Martin
- Marek Ancukiewicz
- Matija Snuderl
- Mehra Golshan
- Rakesh Jain
- Saloni R. Jain
- Sara M Tolaney
- Shom Goel
- Steven J. Isakoff
- William T. Barry
- Yves Boucher
Organizations
- AIRC - The Italian Foundation for Cancer Research
- Harvard Medical School
- Massachusetts Institute of Technology
- National Cancer Institute
- Roche (United States)
- Susan G. Komen for the Cure
- United States Department of Defense